Guidance Documents

Q&A asking if a pharmacy may deliver a prescribed buprenorphine product to a practitioner for direct administration to the patient. This Q&A further explains that a pharmacy may deliver buprenorphine to the registered location of either the prescribing or the administering practitioner, and must be administered by injection or implantation only to the patient named on the prescription within 14 days after the date of receipt of the CS by the practitioner.

Question and Answer addressing if a Researcher registrant should complete a DEA Form 222 when participating in double-blind studies in which the exact quantity of schedule I or II controlled substances received is unknown.

FAQs regarding the Industry Replacement of Tommy Built Tactical Model T36 Receiver.

This guidance document addresses issues pertaining to an individual practitioner’s use of their home address as a principal place of business or professional practice and the home address becoming controlled premises subject to unannounced inspections and administrative warrants under existing Drug Enforcement Administration (DEA) regulations

Template letter explaining process and documentation requested for remote quality of service reviews of approved credit counseling agencies

The guidance is intended to help businesses understand how they can work together to rebuild affected communities without violating the antitrust laws.

This manual was prepared by the Drug Enforcement Administration (DEA), Diversion Control Division, to assist those persons who handle scheduled listed chemical products and List I and II chemicals in understanding the Federal Controlled Substances Act and its implementing regulations as they pertain to regulated chemicals.

The DEA Researchers Manual is a guide for registrants and the public as to the rights and obligations of registrants under the CSA and its implementing regulations.

The Bureau has been asked to determine the applicability of Titles I and II of the Gun Control Act of 1968 (Chapter 44 of Title 18 U.S.C., and Chapter 53 of Title 26 U.S.C. (National Firearms Act)) to a device known as the Taser, a hand-held device designed to expel by means of an explosive two electrical contacts (barbs) connected by two wires attached to a high voltage source in the device. 

The purpose of this letter is to provide all federal explosives licensees and permittees guidance on the safe storage of explosive materials. Electronic nicotine delivery systems, or other similar devices, are electronic devices that, through an aerosolized solution, deliver nicotine, flavor, and/or other substances (including non-tobacco products) to the user inhaling from the device.

This letter provides guidance on your obligations as a federal firearms licensee. The guidance is intended to assist you in meeting these obligations. This letter does not impose any new obligations. It merely confirms the continuing applicability of existing federal obligations.

The purpose of this open letter is to advise you that the Louisiana Lifetime Concealed Handgun Permit (Lifetime Permit) meets the requirements as an alternative to the National Instant Criminal Background Check System (NICS) check only during the five-year period beginning on the date of issuance of the Lifetime Permit.